Work

Développement et optimisation de poudres contenant des liposomes pour l'administration pulmonaire

Year: 2026
Type: dissertation
Abstract: Pulmonary drug delivery is a promising strategy for treating chronic respiratory diseases, as it enables high local drug concentrations while minimizing systemic side effects. However, its effectiveness is often limited by physiological barriers that hinder drug deposition and therapeutic efficiency. To address this, liposomes have emerged as attractive carriers, enabling the encapsulation of active pharmaceutical ingredients, their protection from degradation and improved bioavailability, although their limited aqueous stability remains a major challenge. In this context, formulating liposomes as dry powders for inhalation represents a relevant approach to enable efficient pulmonary delivery and improve stability. Spray-drying, a widely used technique to produce respirable particles, allows control over powder properties but may also compromise liposome integrity and induce premature drug leakage. This thesis therefore aimed to evaluate the feasibility of developing optimized inhalable liposome-based dry powder formulations. A Quality by Design approach supported by Design of Experiments was implemented to assess the feasibility of spray-drying liposomes and to identify critical formulation and process parameters. This work provided fundamental insights into the impact of drying conditions and liquid feed composition on liposome integrity and powder properties. Liposome stability during spray-drying was shown to depend on a complex interplay of factors, where active ingredient properties influence susceptibility to leakage, while lipid composition, excipient environment and process conditions govern membrane response to stress and powder properties. These findings highlight the need to consider liposomal systems as integrated formulations. Additionally, optimized spray-drying conditions were identified and validated, enabling the production of inhalable powders with preserved liposome integrity, limited drug leakage and suitable aerodynamic properties, resulting in high in vitro lung deposition (FPF ~70%). Subsequently, optimized inhalable dry powder formulations were developed, incorporating an innovative combination of ciclesonide and indacaterol for asthma treatment, which is not currently available on the pharmaceutical market in this form. The spray-drying conditions identified were successfully applied to liposomes designed to co-encapsulate this combination for pulmonary delivery, yielding inhalable powders with preserved liposome integrity, enhanced lung deposition and satisfactory stability under refrigerated conditions. In parallel, the same drug combination was formulated into non‐liposomal inhalable dry powders, including a clinically relevant optimized formulation and a reference formulation matched in composition and drug content to the optimized liposome‐based DPI, enabling assessment of the added value of liposomal incorporation. Overall, this work demonstrates the feasibility of developing liposome-based inhalable dry powders, highlights the challenges associated with their formulation and provides a better understanding of the parameters governing their performance. These findings establish a solid foundation for the design of next generation inhalable formulations and open new perspectives for the development of more efficient and targeted therapeutic strategies for the treatment of respiratory diseases.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7167754708
Cites: 467
Cited by:
Related to: 10